Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-13 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatic Impairment
- Moderate Hepatic Impairment
Intervention
- Drug: Zanzalintinib — also filed as XL092
Primary outcomes
what the primary-completion date above is the date OFArea Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time t Corresponding to the Last Quantifiable Concentration (AUC0-t) of Zanzalintinib
measured Predose up to 7 days postdose
Maximum Observed Plasma Drug Concentration (Cmax) of Zanzalintinib
measured Predose up to 7 days postdose
Time to Cmax (Tmax) of Zanzalintinib
measured Predose up to 7 days postdose
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed